Bit Digital Inc vs Novartis AG — how do they compare? Bit Digital Inc trades at $1.48 (market cap $471.05M), while Novartis AG trades at $154.71 (market cap $295.37B). The key difference: Novartis AG is far larger — about 627× Bit Digital Inc's market cap, and Novartis AG pays a 3.07% dividend while Bit Digital Inc pays none. Which is the better fit depends on your goals.
| BTBT | NVS | |
|---|---|---|
Market Cap | $471.05M | $295.37B |
Sector | Technology | Health |
52-Week High | $4.22 | $168.62 |
52-Week Low | $1.23 | $119.31 |
Enterprise Value | $760.36M | $336.69B |
Dividend Yield | — | 3.07% |
Signals from Pluang's Aura AI — not financial advice
BTBT trades at $1.46, up 12.31% today, but the technical outlook is bearish with selling pressure outweighing buying signals. Fundamentally, the company reported a net loss of $80.32 million in 2025, with a negative net income margin of -145.45% in 2026, indicating severe profitability challenges despite a gross margin above 55%. Recent earnings have missed expectations in two of the last three quarters.
The outlook remains challenged by persistent losses and negative cash flow from operations. While analyst coverage is limited and currently shows a 100% buy rating from two firms, significant execution risk and reliance on financing activities to offset operational cash burns present substantial headwinds for shareholder value appreciation in the near term.
Novartis (NVS) trades at $152.41, down 2.79% today, with technical indicators showing neutral momentum near key support at $152. The company reported strong Q2 2026 earnings that beat expectations, driven by oncology drug performance, while maintaining a robust 22.5% net margin and $56.7B in revenue. Recent institutional buying activity and a predominantly Hold analyst consensus reflect cautious optimism amid patent expiration headwinds.
The outlook balances strong fundamentals and pipeline progress against generic competition risks. Investment appeal lies in dividend stability and new drug growth, though Entresto sales decline and U.S. pricing pressures require monitoring. The stock presents a defensive opportunity with moderate upside potential if newer therapies continue outperforming.
Trailing returns across standard periods
Latest headlines on both assets
Bit Digital is a sustainability-focused digital asset production company. It primarily engages in Bitcoin mining and Ethereum staking while also providing high-performance computing (HPC) infrastructure for AI applications.
Read more on BTBT →Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →